He enzyme kūlohelohe ka Nattokinase i unuhi ʻia mai ka natto, kahi meaʻai Kepanī kuʻuna i hana ʻia ma ka hoʻoulu ʻana i nā soybeans me Bacillus subtilis natto. Ua loaʻa iā ia ka hoihoi ʻepekema ma muli o kona kuleana kūpono i ke kākoʻo ʻana i ke olakino cardiovascular, ke kahe koko olakino, a me ke kahe koko maʻamau. Ua ʻike nui ʻia ʻo Nattokinase no kāna hana fibrinolytic, ʻo ia hoʻi, hiki ke kōkua i ke kākoʻo ʻana i ke kaʻina hana kūlohelohe o ke kino o ka wāwahi ʻana i ka fibrin, kahi protein e pili ana i ka hoʻokumu ʻana o ke koko clot.
ʻAʻole e like me nā mea kanu he nui, he mea hana enzyme ka nattokinase. Ua aʻo ʻia no kona hopena hiki ke hoʻopilikia i ke koko, ka mānoanoa o ke koko, nā māka pili i ke koko, ka metabolism lipid, a me ke olakino o nā kīʻaha koko. Eia nō naʻe, ke hoʻomohala nei nā hōʻike i loaʻa, a ʻokoʻa nā hopena ma muli o ka nui o ka lāʻau, ka hoʻolālā noiʻi, ka heluna kanaka, a me ka lōʻihi. Aia ma lalo iho kekahi mau pono olakino o ka nattokinase e pili ana i ka noiʻi ʻepekema.
1. Kākoʻo i ke kahe koko olakino a me ka hana Fibrinolytic
Hiki i ka Nattokinase ke kākoʻo i ke kahe koko olakino ma ke kōkua ʻana i ke kino e mālama i ke kaulike fibrin maʻamau a me nā ʻano hana haki clot kūlohelohe.
Ma kahi loiloi i kapa ʻia ʻo Nattokinase: He Luna Antithrombotic Waha no ka Kāohi ʻana i nā Maʻi Cardiovascular, ua wehewehe nā kānaka noiʻi i ka nattokinase ma ke ʻano he enzyme fibrinolytic me nā waiwai kākoʻo cardiovascular. Ua wehewehe ka loiloi e hiki i ka nattokinase ke kōkua i ka wāwahi pololei ʻana i ka fibrin a hiki ke kākoʻo i ka ʻōnaehana fibrinolytic ponoʻī o ke kino ma o ka hoʻohuli ʻana i ka plasmin a me nā ala ʻē aʻe e pili ana i ka clot. Hōʻike kēia mau ʻano hana e hiki i ka nattokinase ke pāʻani i kahi kuleana i ke kākoʻo ʻana i ke kahe koko olakino a me ka hana vascular (Weng et al., 2017).
ʻO kekahi loiloi ʻē aʻe, ʻo Nattokinase: He Koho Kūpono no ka Pale ʻana a me ka Mālama ʻana i nā Maʻi Cardiovascular, ua kūkākūkā i ka nattokinase ma ke ʻano he hoʻokahi o nā ʻāpana hana nui loa o ka natto. Ua hōʻike nā mea kākau i kona hopena kūpono ma ka fibrinolysis, ke koko, ka metabolism lipid, a me nā māka e pili ana i ka atherosclerosis. Eia nō naʻe, ua ʻike pū lākou he pono nā haʻawina kanaka hou aʻe e hōʻoia i kona pilina lapaʻau, ka dosage kūpono, a me ka palekana lōʻihi i nā heluna kanaka like ʻole (Chen et al., 2018).
2. Hiki ke kōkua i ka mālama ʻana i ke koko koko olakino
Ua aʻo ʻia ʻo Nattokinase no kona kūlana kūpono i ke kākoʻo ʻana i ke koko koko maʻamau, ʻoi aku hoʻi i nā poʻe me nā pae koko kiʻekiʻe.
Ma kahi hoʻokolohua randomized, double-blind, placebo-controlled, ua aʻo nā kānaka noiʻi i 86 mau mākua i piha i ka makahiki 20 a 80 me ke koko systolic i mālama ʻole ʻia ma waena o 130 a me 159 mmHg. Ua loaʻa i nā mea komo ka nattokinase ma 2,000 FU i kēlā me kēia lā a i ʻole kahi placebo no 8 mau pule. Ua hoʻopau nā mea komo he kanahikukūmākolu i ke aʻo ʻana. I ka hoʻohālikelike ʻia me ka placebo, ua pili ka nattokinase me ka emi ʻana o ke koko systolic a me ka diastolic, me nā loli net o kahi -5.55 mmHg a me -2.84 mmHg, kēlā me kēia. Ua ʻike pū ka haʻawina i ka emi ʻana o ka hana plasma renin, e hōʻike ana i kahi ʻano hana e pili ana i ka hoʻoponopono ʻana i ke koko (Kim et al., 2008).
Ma kekahi noiʻi ʻAmelika ʻĀkau ʻē aʻe i hoʻokaʻawale ʻia, makapō pālua, placebo-controlled, ua hoʻopau nā mea komo 79 me ke koko kiʻekiʻe i 100 mg nattokinase i kēlā me kēia lā a i ʻole placebo no 8 mau pule. Ua nānā ke aʻo ʻana i ke koko a me nā māka pili i ka pilikia cardiovascular, me ka von Willebrand factor. Ua hōʻike nā ʻike ua pili ka hoʻohana ʻana i ka nattokinase me ka emi ʻana o ke koko a me ka emi ʻana o ka von Willebrand factor, kahi māka e pili ana me ke olakino vascular a me ka hana clotting (Jensen et al., 2016).
Hōʻike kēia mau haʻawina e hiki i ka nattokinase ke kākoʻo i ke kaulike o ke koko i kekahi mau hui. Eia nō naʻe, ʻaʻole pono e manaʻo ʻia he pani no ka lāʻau antihypertensive i kuhikuhi ʻia a i ʻole ka mālama olakino.
3. Hiki ke kākoʻo i ke kaulike o ka māka pilikia cardiovascular
Hiki i ka Nattokinase ke kōkua i ke olakino cardiovascular ma o ka hoʻohuli ʻana i nā māka i koho ʻia e pili ana i ke kāpili ʻana o ke koko, ka hana o nā kīʻaha koko, a me ke kahe ʻana o ke koko.
He mea pili loa ke aʻo ʻana a Jensen et al. (2016) no ka mea, ʻaʻole ia i nānā wale i ke koko koko akā ua ana pū ʻia ka von Willebrand factor a me ka platelet factor-4. Pili ka Von Willebrand factor i ka hoʻopili ʻana o ka platelet a me ka hoʻokumu ʻana o ke clot. ʻO ka emi ʻana o kēia māka e hōʻike paha i kahi hopena kākoʻo i ke kaulike vascular a me ke kahe koko. Eia naʻe, ʻaʻole kēia manaʻo e pale aku ka nattokinase i nā hanana cardiovascular, no ka mea, pono nā hoʻokolohua lapaʻau nui a lōʻihi e hōʻoia i kēlā mau hopena (Jensen et al., 2016).
Ua loiloi ʻia kahi loiloi ʻōnaehana a me ka meta-analysis o 2023 i kapa ʻia ʻo Nattokinase Supplementation and Cardiovascular Risk Factors i nā hoʻokolohua i hoʻomalu ʻia ma nā māka nattokinase a me nā māka cardiovascular. Ua ʻike ka loiloi ua pili ka hoʻohui nattokinase me ka hōʻemi iki ʻana i ke koko systolic a me diastolic. Eia nō naʻe, ua ʻike pū nā mea kākau ʻaʻole kūlike ka hōʻike no nā māka ʻē aʻe, me nā hopena lipid a me ka coagulation, ma nā haʻawina (Li et al., 2023).
Ma keʻano holoʻokoʻa, hiki i ka nattokinase ke kākoʻo i nā māka cardiovascular i koho ʻia, akā ʻike ʻia kona hopena e hilinaʻi ana i ka heluna kanaka i aʻo ʻia, ka nui o ka lāʻau, ka hoʻohālikelike ʻana o ka huahana, a me ka lōʻihi o ka hoʻohana ʻana.
4. Hiki ke kōkua i ke kākoʻo ʻana i ka Lipid Metabolism a me ke olakino Arterial
Ua hōʻike kekahi mau noiʻi e hiki i ka nattokinase ke kākoʻo i ka metabolism lipid a me ke olakino arterial, akā ʻaʻole i kūlike loa nā hōʻike.
Ma kahi noiʻi lapaʻau ma ka atherosclerosis o ke aʻa carotid a me ka hyperlipidemia, ua noiʻi ʻia ka hoʻohui nattokinase no kona hopena ma ka mānoanoa o ke carotid intima-media, ka nui o ka plaque, a me ka ʻikepili lipid. Ua hōʻike nā ʻike e hiki i ka nattokinase ke hōʻemi i nā ana e pili ana i ka plaque a hoʻomaikaʻi i kekahi mau māka lipid i nā mea komo me ka atherosclerosis a me nā lipids kiʻekiʻe (Ren et al., 2017).
Ua nānā ʻia kahi noiʻi ma hope aku i kahi mahele kiʻekiʻe o ka nattokinase i kēlā me kēia lā, 10,800 FU i kēlā me kēia lā, e pili ana i ka holomua o ka atherosclerosis a me ka hyperlipidemia. Ua hōʻike nā mea noiʻi ua pili kēia mahele me ka hoʻomaikaʻi ʻana i ka ʻikepili lipid a me nā ana e pili ana i ka atherosclerosis. Eia nō naʻe, ʻaʻole pono e hoʻonui ʻia nā ʻike mahele kiʻekiʻe i nā huahana nattokinase āpau a i ʻole nā helu hoʻohui maʻamau me ka ʻole o ka loiloi pono (Chen et al., 2022).
I ka manawa like, ʻaʻole i hōʻike nā haʻawina āpau i nā hopena maikaʻi. ʻO ka Nattokinase Atherothrombotic Prevention Study, kahi hoʻokolohua i hoʻomalu ʻia i nā poʻe olakino me ka pilikia cardiovascular haʻahaʻa, ua ʻike ʻia ʻaʻole i hoʻopilikia nui ka hoʻohui nattokinase i ka holomua o ka subclinical atherosclerosis, ke koko, a i ʻole nā māka hoʻokolohua ma hope o ka manawa mālama waena o 3 mau makahiki (Hodis et al., 2021).
Hōʻike kēia ʻokoʻa e ʻoi aku ka pili o ka nattokinase i nā heluna kanaka i koho ʻia, ʻoi aku hoʻi ka poʻe me nā kumu pilikia cardiovascular kikoʻī, ma mua o ka poʻe olakino haʻahaʻa ka pilikia.
5. Hiki ke hāʻawi i ke kākoʻo ma ke ʻano he ʻāpana o kahi ala olakino Cardiometabolic
I kekahi manawa ua aʻo ʻia ʻo Nattokinase me nā mea hana ʻē aʻe, ʻoi aku hoʻi i ka noiʻi olakino cardiometabolic.
Ma kahi hoʻokolohua randomized, double-blind, placebo-controlled i ka makahiki 2024, ua aʻo nā mea noiʻi i ka nattokinase i hui pū ʻia me ka laiki hū ʻulaʻula i nā poʻe maʻi me ka maʻi ʻaʻai coronary paʻa. Ua ʻimi ke aʻo ʻana i nā hopena hoʻohaʻahaʻa lipid, antihypertensive, a me antithrombotic. Ua hōʻike nā hopena e hiki i ka hui pū ʻana ke hoʻomaikaʻi i kekahi mau ʻano cardiometabolic, ʻoiai he mea nui e hoʻomaopopo he haʻawina hui pū kēia. No laila, ʻaʻole hiki ke hoʻopili ʻia nā pono i ka nattokinase wale nō (Liu et al., 2024).
He mea nui kēia ʻano noiʻi no ka mea ua hoʻopili ʻia ke olakino cardiovascular e nā kumu he nui, me ka ʻai, ka hana kino, nā pae lipid, ke koko, ka mumū, ke kaumaha oxidative, a me nā genetics. Hiki i ka Nattokinase ke kūpono i loko o kahi hoʻolālā olakino ākea, akā pono e kau ʻia ma ke ʻano he mea kākoʻo ma mua o kahi hopena kū hoʻokahi.
6. Hoʻomanawanui maikaʻi ʻia, akā pono ke mālama
ʻIke ʻia ua ʻae maikaʻi ʻia ka Nattokinase i kekahi mau noiʻi kanaka, akā pono ka hoʻohana pono ʻana ma muli o kona hopena i nā ala koko.
Ua loiloi ʻia kahi noiʻi lapaʻau maoli i ka nattokinase ma 100 mg i kēlā me kēia lā i nā poʻe maʻi i ʻae ʻia i ke ʻoki ʻana o ke koko. Ua hōʻike nā mea noiʻi i nā nānā ʻana e kākoʻo ana i ka palekana o ka hoʻohana ʻana i ka nattokinase ma kēia ʻano, ʻoiai he mea nui ka nānā ʻana o ke kauka pilikino, ʻoiai no ka poʻe e lawe ana i nā lāʻau anticoagulant a i ʻole antiplatelet.Gallelli et al., 2021).
ʻOiai hiki i ka nattokinase ke hoʻopilikia i ka fibrinolysis a me nā māka pili i ke koko, ʻaʻole paha ia e kūpono no nā mea āpau. Pono ka poʻe e lawe ana i nā lāʻau hoʻokahe koko, aspirin, anticoagulants, a i ʻole nā lāʻau antiplatelet, a me ka poʻe me nā maʻi kahe koko, ke ʻoki kino e hiki mai ana, ka hāpai ʻana, a i ʻole nā maʻi koʻikoʻi, e ʻimi i ka ʻōlelo aʻoaʻo lapaʻau ma mua o ka hoʻohana ʻana i ka nattokinase.
He enzyme kū hoʻokahi ʻo Nattokinase i loaʻa mai nā soybeans i hoʻoulu ʻia a ua ʻike nui ʻia no kona kuleana kūpono i ke kākoʻo ʻana i ke olakino cardiovascular a me ke kahe koko. ʻO kāna mau wahi noiʻi ikaika loa:
- Kākoʻo kahe koko olakino
- Hana Fibrinolytic
- Ke kaulike o ke koko
- Kākoʻo māka vascular
- ʻO ka metabolism lipid a me ke olakino arterial i nā heluna kanaka i koho ʻia
He mea hoʻohiki nā noiʻi i loaʻa, akā ʻaʻole kūlike loa. Hōʻike kekahi mau noiʻi i nā hoʻomaikaʻi koʻikoʻi i ke koko, ka hana fibrinolytic, a me nā māka cardiovascular, aʻo nā mea ʻē aʻe e hōʻike ana i ka hopena palena a ʻaʻohe hopena paha, ʻoiai i nā poʻe olakino haʻahaʻa. Hōʻike kēia e hana like ʻole paha ka nattokinase ma muli o ke kūlana olakino o kēlā me kēia kanaka, ka nui, ka lōʻihi, a me ka maikaʻi o ka huahana.
Pono e nānā ʻia ʻo Nattokinase ma ke ʻano he mea hana kākoʻo ma mua o kahi lāʻau lapaʻau a lāʻau lapaʻau paha. Ke hoʻohana pono ʻia, hiki ke lilo i mea hoʻohui waiwai i nā ʻano hana olakino cardiovascular, ʻoiai nā mea i kālele ʻia i ke kahe koko, ka ʻelemakule olakino, a me ke kaulike metabolic.
Akahana: ʻAʻole i loiloi ʻia ka ʻōlelo e ka EFSA, KFDA a i ʻole FDA. ʻAʻole i manaʻo ʻia kēia huahana e ʻike, mālama, ho'ōla, a pale paha i kekahi maʻi. ʻOiai ua hoʻokumu ʻia ka ʻike i hāʻawi ʻia ma nā kuhikuhi hilinaʻi, ʻaʻole mākou e hana i kekahi mau koi a i ʻole nā hōʻoia kikoʻī. He mea nui e kūkākūkā me kāu kākā'ōlelo mālama ola no ka ʻōlelo aʻoaʻo pilikino a me ke alakaʻi e pili ana i kou olakino.
E hoʻomaopopo '
- Chen, H., McGowan, EM, Ren, N., Lal, S., Nassif, N., Shad-Kaneez, F., Qu, X. a me Lin, Y., 2018. Nattokinase: He koho ʻē aʻe hoʻohiki i ka pale ʻana a me ka mālama ʻana i nā maʻi cardiovascular. Nā ʻIke Biomarker, 13, p.1–8.
- Chen, H., McGowan, EM, Ren, N., Lal, S., Nassif, N., Shad-Kaneez, F., Qu, X. a me Lin, Y., 2022. Hoʻoponopono maikaʻi i ka holomua atherosclerosis a me ka hyperlipidemia me ka nattokinase. Nā palena i ka lāʻau lapaʻau Cardiovascular.
- Gallelli, G., Cione, E., Caroleo, MC, Carullo, G., Genchi, G., Rende, P. a me Citraro, R., 2021. Kākoʻo nā ʻikepili i hoʻopaʻa ʻia ma ke ola maoli i ka palekana o ka nattokinase i nā maʻi me nā maʻi vascular. Nā meaʻono, 13 (6), p.2031.
- ʻO Hodis, HN, Mack, WJ, Dustin, L., Mahrer, PR lāua ʻo Azen, SP, 2021. Haʻawina pale atherothrombotic Nattokinase: He hoʻokolohua i hoʻomalu ʻia ma kahi randomized. ʻO ka Hemorheology Lapaʻau a me ka Microcirculation, 78 (4), pp.339-353.
- ʻO Jensen, GS, Lenninger, M., Ero, MP lāua ʻo Benson, KF, 2016. ʻO ka hoʻohana ʻana i ka nattokinase e pili ana me ka hoʻemi ʻana i ke koko a me ka von Willebrand factor, kahi māka pilikia cardiovascular: Nā hopena mai kahi hoʻokolohua lapaʻau randomized, double-blind, placebo-controlled, multicenter North American. Ka Mana Hoʻomalu Koko Hoʻohui ʻia, 9, p.95–104.
- ʻO Kim, JY, Gum, SN, Paik, JK, Lim, HH, Kim, KC, Ogasawara, K., Inoue, K., Park, S., Jang, Y. lāua ʻo Lee, JH, 2008. Nā hopena o ka nattokinase ma ke koko: He hoʻokolohua randomized, i kāohi ʻia. Ka noiʻi ʻana i ka maʻi hypertension, 31 (8), pp.1583-1588.
- Li, X., Zheng, X., Liu, Y. a me Zhang, Y., 2023. Ka hoʻohui ʻana o Nattokinase a me nā mea pilikia cardiovascular: He loiloi ʻōnaehana a me ka meta-analysis. Nānā i ka lāʻau lapaʻau maʻi cardiovascular, 24 (8), p.234.
- ʻO Liu, M., Zhang, H., Wang, Y., Li, X. a me Chen, J., 2024. Nā hopena hoʻohaʻahaʻa lipid, antihypertensive, a me nā antithrombotic o ka nattokinase i hui pū ʻia me ka laiki hū ʻulaʻula i nā maʻi me ka maʻi artery coronary paʻa: He hoʻokolohua randomized, double-blinded, placebo-controlled. Nā Pākia ma Nutrition.
- Ren, NN, Chen, HJ, Li, Y., McGowan, E. lāua ʻo Lin, YG, 2017. He noiʻi lapaʻau e pili ana i ka hopena o ka nattokinase ma ka atherosclerosis o ke aʻa carotid a me ka hyperlipidaemia. Zhonghua Yi Xue Za Zhi, 97 (26), pp.2038-2042.
- Weng, Y., Yao, J., Sparks, S. lāua ʻo Wang, KY, 2017. Nattokinase: He mea antithrombotic waha no ka pale ʻana i nā maʻi cardiovascular. ʻO ka International Journal of Molecular Sciences, 18 (3), p.523.
